Efficacy and safety of Weifuchun tablet for chronic atrophic gastritis: A systematic review and meta-analysis.xlsx

The data was related to the research" Efficacy and safety of Weifuchun tablet for chronic atrophic gastritis: A systematic review and meta-analysis". Fifteen RCTs were enrolled in this meta-analysis. <strong>Search strategy</strong> This study was enrolled at PROSPERO (registration number: CRD42022365703; http://www.crd.york.ac.uk/prospero). Databases, including Cochrane Library, EMBASE, PubMed, China National Knowledge Infrastructure (CNKI), Wanfang database, Chinese Scientific Journals Database (VIP) and Chinese Biological Medical Database (CBM), were searched up their inception to October 5, 2022. In addition, we also searched the Chinese Clinical Trial Registry and ClinicalTrials.gov. Two researchers conducted and screened all the citations independently. We conducted a retrieval combined Mesh terms with free words, and a complete list of retrieval strategies for PubMed was described below: #1. gastritis, atrophic [Mesh Terms] #2. ((((((' Atrophic Gastriti* '[Title/Abstract]) OR ('precancerous conditions'[Title/Abstract])) OR (Metaplasia [Title/Abstract])) OR ('Gastric premalignant'[Title/Abstract])) OR ('Intestin* metaplasia'[Title/Abstract])) OR (Dysplasia [Title/Abstract])) OR ('gastric atrophy'[Title/Abstract]) #3. (Weifuchun [Title/Abstract]) OR (WFC[Title/Abstract]) #4. #1 OR #2 #5. #4 AND #3 #6. (((('Randomized Controlled Trial'[Publication Type]) OR ('Controlled Clinical Trial'[Publication Type])) OR (Randomized [Title/Abstract])) OR (Placebo [Title/Abstract])) OR (Randomly [Title/Abstract]) #7. #5 AND #6 <strong>Selection criteria</strong> Retrieved results were imported into EndNote X9.1. Two researchers (Longhua Wang and Ping Li) independently evaluated the qualification of retrieval studies according to inclusion criteria. A preliminary screening was performed by browsing titles and abstracts independently. Based on browsing titles and abstracts, studies including case reports, experience introductions, reviews, animal studies, irrelevant to our topic and non-randomized controlled trials were excluded. We also excluded studies combined WFC with other therapies. A next step screening was conducted and the study was temporarily adopted if there was no clear exclusion information. Two researchers(Longhua Wang and Ping Li)independently performed a next step screening by browsing a full text. Based on reading the full article, we strictly screened the selected studies according to inclusion criteria. If divergences existed, we would discuss with a third researcher (Xia Ding). Studies were included according to inclusion criteria as follows. 1) The studies were randomized controlled trials (RCTs) published in Chinese or English before October 5, 2022, and no restriction on the implementation of blinding. 2) The study subjects were adult patients with CAG diagnosed by endoscopy and pathology. The gender and source of the cases were not limited. 3) The experiment group was treated with Weifuchun tablet alone, but interventions of control group included western medicine, Chinese herbal compound, Chinese patent drugs, or placebo.4) Duration of course was no fewer than 3 months. <strong>Data extraction and quality assessment</strong> Data extraction was done by two investigators independently (Longhua Wang and Lan Li), containing literature title, the first author, date of publication, study population and baseline data consistency, sample size, intervention measures, duration, outcome evaluation indicators and results, follow-up time and adverse drug events. If divergences existed, we would discuss with a third researcher (Shuying Ru). Methodological quality of RCTs was assessed by Cochrane risk of bias tool, containing seven criteria (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias). Two researchers (Longhua Wang and Fenglei Wang) conducted methodological quality assessment standalone, and given a bias assessment graded low, high or unknown risk. Inconsistencies were resolved by discussion with all researchers. <br>

本数据关联研究《胃复春片治疗慢性萎缩性胃炎的疗效与安全性：系统评价与荟萃分析》。本次荟萃分析共纳入15项随机对照试验（Randomized Controlled Trials, RCTs）。
<strong>检索策略</strong> 本研究已在国际前瞻性系统评价注册平台（PROSPERO）注册（注册号：CRD42022365703；http://www.crd.york.ac.uk/prospero）。检索数据库包括考克兰图书馆（Cochrane Library）、荷兰医学文摘数据库（EMBASE）、PubMed数据库、中国知网（China National Knowledge Infrastructure, CNKI）、万方数据库、中文科技期刊数据库（Chinese Scientific Journals Database, VIP）以及中国生物医学文献数据库（Chinese Biological Medical Database, CBM），检索时限均为自建库至2022年10月5日。此外，本研究还检索了中国临床试验注册中心（Chinese Clinical Trial Registry）与ClinicalTrials.gov平台。由2名研究者独立完成所有文献的筛选与筛查工作。检索采用医学主题词（Mesh terms）结合自由词的组合方式，PubMed的完整检索策略如下：
#1. 萎缩性胃炎 [医学主题词（Mesh Terms）]
#2. （（（（（（"Atrophic Gastriti*"[题名/摘要]）OR（"precancerous conditions"[题名/摘要]））OR（Metaplasia [题名/摘要]））OR（"Gastric premalignant"[题名/摘要]））OR（"Intestin* metaplasia"[题名/摘要]））OR（Dysplasia [题名/摘要]））OR（"gastric atrophy"[题名/摘要]）
#3. （Weifuchun [题名/摘要]）OR（WFC[题名/摘要]）
#4. #1 OR #2
#5. #4 AND #3
#6. （（（（"Randomized Controlled Trial"[出版类型]）OR（"Controlled Clinical Trial"[出版类型]））OR（Randomized [题名/摘要]））OR（Placebo [题名/摘要]））OR（Randomly [题名/摘要]）
#7. #5 AND #6
<strong>纳入标准</strong> 检索得到的结果导入文献管理软件EndNote X9.1中。由2名研究者（王龙华、李平）独立根据纳入标准评估检索所得研究的合格性。首先通过独立浏览题名与摘要进行初筛，排除病例报告、经验介绍、综述类文献、动物实验、与本研究主题无关的文献以及非随机对照试验，同时排除联合胃复春与其他治疗方案的研究。若文献无明确排除依据，则暂时纳入待下一步筛查。随后由2名研究者（王龙华、李平）独立通过阅读全文进行第二轮筛查。基于全文阅读结果，严格按照纳入标准筛选研究。若存在分歧，则与第三位研究者（丁霞）讨论协商。最终纳入研究需满足以下标准：
1) 2022年10月5日前发表的中英文随机对照试验（Randomized Controlled Trials, RCTs），不限制盲法实施情况；
2) 研究对象为经内镜与病理诊断确诊的慢性萎缩性胃炎（Chronic Atrophic Gastritis, CAG）成年患者，性别与病例来源不限；
3) 试验组仅采用胃复春片单一治疗，对照组干预措施包括西药、中药复方、中成药或安慰剂；
4) 治疗疗程不少于3个月。
<strong>数据提取与质量评估</strong> 由2名研究者（王龙华、李岚）独立完成数据提取，内容包括文献标题、第一作者、发表日期、研究人群与基线数据一致性、样本量、干预措施、治疗疗程、结局评价指标与结果、随访时间以及药品不良反应事件。若存在分歧，则与第三位研究者（茹淑英）讨论协商。采用考克兰偏倚风险评估工具（Cochrane risk of bias tool）对随机对照试验的方法学质量进行评估，该工具包含7项评价标准：随机序列生成、分配隐藏、受试者与研究者盲法、结局评估盲法、不完整结局数据、选择性报告以及其他偏倚。由2名研究者（王龙华、王风雷）独立完成方法学质量评估，将偏倚风险分为低风险、高风险与不确定风险三类。若存在不一致意见，则通过全体研究者讨论解决。